ANG1005 in Leptomeningeal Disease From Breast Cancer
This is an open-label Phase 3 study to see if ANG1005 can prolong survival compared to a Physician Best Choice control in HER2-negative breast cancer patients with newly diagnosed leptomeningeal disease and previously treated brain metastases.
Leptomeningeal Carcinomatosis|Leptomeningeal Metastases|Brain Metastases|HER2-negative Breast Cancer
DRUG: ANG1005|DRUG: Physician's Best Choice
Overall survival, From the date of randomization until death due to any cause, assessed for up to 2 years.
Central nervous system progression-free survival, From the date of randomization until central nervous system progression, assessed for up to 2 years.|Central nervous system clinical benefit rate at 3, 6 and 12 months, At 3, 6 and 12 months.|6-month and 12-month overall survival rates, At 6 and 12 months.|Leptomeningeal carcinomatosis response rate, Assessed for up to 2 years from first patient randomised.|Duration of leptomeningeal carcinomatosis response, Assessed for up to 2 years from first patient randomised.|Overall survival in triple negative breast cancer patients, From the date of randomization until death due to any cause, assessed for up to 2 years.
This is an open-label Phase 3 study to see if ANG1005 can prolong survival compared to a Physician Best Choice control in HER2-negative breast cancer patients with newly diagnosed leptomeningeal disease and previously treated brain metastases.